Closes with security.
Leaves without a trace.

Mynx Control™
Vascular Closure Device
Close with Confidence. Leave Nothing Behind.

The innovative design and predictable deployment of MYNX CONTROL™ Vascular Closure Device (VCD) delivers outstanding performance and control, for consistently secure arterial closures.

The Science of Active Extravascular Sealing

MYNX® GRIP TIP  MYNX® Sealant

MYNX CONTROL™ VCD is comprised of two configurations of polyethylene glycol (PEG), for durable hemostasis.

Proven PEG Material

- **SAFE**  No foreign-body reaction or scar tissue formation
- **SYNTHETIC**  Non-thrombogenic
- **HYDROLYTIC DEGRADATION**  Fully resorbs through hydrolysis—no enzymatic breakdown

Dual-mode Active Sealing

1. MYNX® GRIP TIP
2. MYNX® SEALANT COLUMN

FULLY EXTRAVASCULAR CLOSURE

- Activated by body temperature and pH
- Interlocks with contours of the vessel by actively attaching to the artery, for secure mechanical closure
- Expands to 3-4 times its original size on contact with blood and subcutaneous fluids, creating a matrix structure for clot formation
- Provides further support for the MYNX® GRIP TIP

30 DAY RESORBABILITY*

Secure Extravascular Closure

in a wide range of clinical scenarios

With exceptional versatility, MYNX CONTROL™ VCD offers dependable closure with nothing left behind—even in cases where using a different vascular closure device might be unsuitable.

Safe for bifurcations†

Useful on antegrade punctures

No footplates, sutures, or metal implants to impede reaccess

Balloon visualization verifies position

---

*The sealant hydrolyzes within 30 days; the body’s own healing mechanisms are the sole mechanism of action beyond 30 days. P. 2; MYNX CONTROL FDA Submission: # P040044/S079
†Confirm vessel size is ≥ 5 mm
MYNX® VCD has been clinically proven to reduce surgical complications, expedite recovery, shorten hospital stays, and increase patient comfort.2-7‡

Established Safety and Efficacy in Interventions
A single-center, multi-year comparative analysis involving 4,074 percutaneous coronary intervention (PCI) patients found MYNX® VCD to be equally safe and effective as Angio-Seal™, with no intra-arterial components left behind.4

Proven Safe in Clinical Trials and Real-world Use
In a prospective multi-center, non-randomized clinical trial (n=190) MYNX® VCD demonstrated:2,8

Access-site bleeding and vascular injury4

<table>
<thead>
<tr>
<th>Procedure success rate</th>
<th>Time to hemostasis</th>
<th>Same-day discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.5%</td>
<td>1.3 MIN</td>
<td>99.5%</td>
</tr>
</tbody>
</table>

Reduced Risk and Severity of Complications
In a retrospective, single-center review of 11,006 cardiac and peripheral vascular procedures, MYNX® VCD was proven to reduce the risk and severity of surgical complications following catheterization, compared to Angio-Seal™ and manual compression.5

Increased Patient Comfort
In a blinded, randomized clinical study, pain at closure and pain increase from baseline to close were significantly lower for MYNX® VCD than Angio-Seal™.7

<table>
<thead>
<tr>
<th>Rate of surgical repair6</th>
<th>0.61%</th>
<th>0.06%</th>
<th>0.19%</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-value</td>
<td>&lt;0.0001</td>
<td>0.14</td>
<td></td>
</tr>
</tbody>
</table>

- 10x fewer secondary surgeries than Angio-Seal™6
- 3x fewer secondary surgeries than manual compression6
- MYNX® VCD complications did not involve embolism or artery damage, worsening of peripheral vascular disease, or necessitate device removal6

<table>
<thead>
<tr>
<th>Less pain than Angio-Seal™</th>
<th>Worst Pain</th>
<th>Pre-closure</th>
<th>Closure</th>
<th>Least Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10</td>
<td>8</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>p-value</td>
<td>0.009</td>
<td></td>
<td></td>
<td>5.03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mean Pain (Visual Analog Scale)</th>
<th>2.94</th>
<th>5.03</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-value</td>
<td>0.009</td>
<td></td>
</tr>
</tbody>
</table>

‡Time to discharge eligibility as compared to manual compression. MATRIX Clinical Trial (IDE# G030182)
The next-generation MYNX CONTROL™ Vascular Closure Device (VCD) deployment system is purpose-designed to enhance safety and deliver reliable performance.

Made for Predictable Deployment. Designed for Ease of Use.

The MYNX® GRIP TIP securely adheres to the artery and MYNX® Sealant fills the tissue tract.

Procedure Steps

1. DEPLOY THE BALLOON
   Achieve temporary hemostasis and position at the arteriotomy.

2. PLACE THE SEALANT
   The MYNX® GRIP TIP securely adheres to the artery and MYNX® Sealant fills the tissue tract.

3. REMOVE THE DEVICE
   Platelets and blood cells collect inside the sealant’s porous matrix.

4. FINAL RESULT
   The sealant dissolves within 30 days leaving nothing behind but a healed artery.

---

$\text{MYNX CONTROL™ VCD is incompatible with Medtronic Input® Introducer (11 cm) sheaths, Cook CheckFlo® Performer™ Introducer sheaths, and procedural sheaths longer than 12 cm in effective length.}$
Closes with Security. Leaves Without a Trace.

MYNX CONTROL™ Vascular Closure Device (VCD) integrates dual-mode active sealing and resorbability with a next-generation delivery system to maximize predictability, safety, and ease of use.

SECURE CLOSURE   SAFETY AND PATIENT COMFORT   EASE OF USE

Ordering Information
The MYNX CONTROL™ VCD includes:

(1) MYNX CONTROL™ VCD including balloon catheter and integrated polyethylene glycol sealant

(1) 10 mL locking syringe

<table>
<thead>
<tr>
<th>SIZE</th>
<th>ORDER NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>5F</td>
<td>MX5060</td>
</tr>
<tr>
<td>6F / 7F</td>
<td>MX6760</td>
</tr>
</tbody>
</table>

To order the MYNX CONTROL™ VCD in the United States contact your local Cordis sales rep or customer service at 800.327.7714. To learn more visit cordis.com/mynx.

REFERENCES:
2. MYNX Control Vascular Closure Device Instructions for Use.
8. MATRIX Clinical Trial (IDE# G030182).

INDICATIONS FOR USE: MYNX CONTROL™ VCD is indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F, or 7F procedural sheath.

PRECAUTIONS: MYNX CONTROL™ VCD should only be used by a trained licensed physician or healthcare professional. MYNX CONTROL™ VCD should not be used in patients with a known allergy to PEG. MYNX CONTROL™ VCD should not be used with sheaths longer than 12 cm effective length or incompatible sheaths listed in Table 9 of the Instructions for Use.

WARNINGS: Do not use if components or packaging appear to be damaged or defective or if any portion of the packaging has been previously opened. DO NOT REUSE OR RESTERILIZE. MYNX CONTROL™ VCD is for single use only. The catheter is loaded with a single hydrogel sealant. Reuse of the device would result in no delivery of hydrogel sealant. Do not use MYNX CONTROL™ VCD if the puncture site is located above the most inferior border of the inferior epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks, since such a puncture site may result in a retroperitoneal hematoma/bleed. Perform a femoral angiogram to verify the location of the puncture site. Do not use MYNX CONTROL™ VCD if the puncture is through the posterior wall or if there are multiple punctures, as such punctures may result in a retroperitoneal hematoma/bleed.

CAUTION: Federal (US) law restricts this device to sale by or on the order of a physician.

IMPORTANT INFORMATION: Prior to use, refer to the Instructions for Use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings, and precautions.

© 2018 Cardinal Health. All rights reserved. CORDIS, the Cordis LOGO, MYNX, and MYNX CONTROL are trademarks or registered trademarks of Cardinal Health and may be registered in the US and/or in other countries. All other trademarks are the property of their respective owners. The MYNX CONTROL™ Vascular Closure Device is manufactured by Cardinal Health and is part of the Cordis portfolio.